Drug-Drug Interaction Study: ASP2151 and Ciclosporin
Condition: Healthy
Intervention: ASP2151 400mg + 100mg ciclosporin; ASP2151 1200mg + 100mg ciclosporin
Intervention MeSH terms: Cyclosporine; Cyclosporins
Phase: Phase 1
Study type: Interventional
Primary purpose: Other
Allocation: Randomized
Intervention model: Crossover Assignment
Masking: None (Open Label)
Enrollment: 26.0
Sex: Male
Minimum age: 18 Years
Maximum age: 45 Years
Healthy volunteers: Accepts Healthy Volunteers
Keywords: HSV; Herpes; volunteers; drug-drug interaction; transplant

Summary:

      ASP2151 is an experimental treatment for herpes. Patients undergoing organ and tissue
      transplantation may be prescribed ciclosporin to suppress their immune system to give the
      transplant an increased chance of not being rejected. A patient with a compromised immune
      system is more susceptible to infections such as herpes, which will require treatment.
    

Eligibility criteria:

        Inclusion Criteria:

          -  A body mass index (Quetelet index) in the range 18.0-30.9 kg/m2.

          -  Sufficient intelligence to understand the nature of the trial and any hazards of
             participating in it. Ability to communicate satisfactorily with the investigator and
             to participate in, and comply with the requirements of, the entire trial.

          -  Willingness to give written consent to participate after reading the information and
             consent form, and after having the opportunity to discuss the trial with the
             investigator or his delegate.

          -  Willingness to give written consent to have data entered into The Overvolunteering
             Prevention System (TOPS).

        Exclusion Criteria:

          -  Clinically relevant abnormal history, physical findings, ECG, or laboratory values at
             the pre-trial screening assessment that could interfere with the objectives of the
             trial or the safety of the volunteer.

          -  Any of the following liver function tests higher than 1.5 times the ULN at the
             screening visit: aspartate aminotransferase (AST), alanine aminotransferase (ALT),
             alkaline phosphatase (ALP), bilirubin, gamma glutamyl transpeptidase (gamma-GT).

          -  Platelet counts outside normal limits.

          -  Presence of acute or chronic illness or history of chronic illness sufficient to
             invalidate the volunteer's participation in the trial or make it unnecessarily
             hazardous.

          -  Clinically significant impaired endocrine, thyroid, hepatic, respiratory or renal
             function, diabetes mellitus, coronary heart disease, or history of any psychotic
             mental illness.

          -  Receipt of a live vaccine in the 3 months before the first dose of study medication,
             or planned immunisation with a live vaccine during the study.

          -  Evidence of any significant bacterial, viral, fungal or parasitic infection during the
             4 weeks before dosing (minor fungal nail infections will not be regarded as
             significant); minor infection (eg common cold) not requiring anti-infective treatment
             during the 2 weeks before dosing.

          -  History of bleeding diathesis.

          -  Surgery (eg stomach bypass) or medical condition that might affect absorption of
             medicines.

          -  Presence or history of severe adverse reaction to any drug, history of multiple drug
             allergies (multiple defined as >3), or sensitivity to trial medication.

          -  Use, during the 28 days before the first dose of trial medication, of any prescription
             medicine, or any other medicine or herbal remedy (such as St John's wort) known to
             interfere with the CYP3A4 metabolic pathway (unless judged as not clinical significant
             by the investigator and sponsor). See Appendix 1 for common CYP3A4
             interactors/substrates.

          -  Use, during the 7 days before the first dose of trial medication, of any
             over-the-counter medicine, with the exception of paracetamol (acetaminophen).

          -  Participation in another clinical trial of a new chemical entity or a prescription
             medicine within the previous 3 months.

          -  Loss of more than 400 mL blood during the 3 months before the trial, eg as a blood
             donor.

          -  Presence or history of drug or alcohol abuse, or intake of more than 21 units of
             alcohol weekly or more than 5 cigarettes daily.

          -  Evidence of drug abuse on urine testing.

          -  Positive test for hepatitis B antigen (HBsAg); or positive test for hepatitis B core
             antibody (HBcAb).

          -  Positive test for hepatitis C, HIV1, HIV2, or active and latent tuberculosis.

          -  Blood pressure and heart rate in seated position at the screening examination outside
             the ranges 90-140 mm Hg systolic, 40-90 mm Hg diastolic; heart rate 40-100 beats/min.

          -  Possibility that the volunteer will not cooperate with the requirements of the
             protocol.

          -  Objection by General Practitioner (GP) to volunteer entering trial.